Dellas Claudia, Loskutoff David J
Department of Cellular Biology, Division of Vascular Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Thromb Haemost. 2005 Apr;93(4):631-40. doi: 10.1160/TH05-01-0033.
Although plasminogen activator inhibitor 1 (PAI-1) is one of the primary regulators of the fibrinolytic system, it also has dramatic effects on cell adhesion, detachment and migration. PAI-1 also differs from other serine protease inhibitors (serpins) in that it is a trace protein in plasma, it has a short half-life in vivo, its synthesis is highly regulated, and it binds to the adhesive glycoprotein vitronectin (VN) with high affinity and specificity. These unique and diverse properties of PAI-1 probably account for the many observations in the literature that correlate abnormalities in PAI-1 gene expression with a variety of pathological conditions. In this review, we discuss the discovery, origin, properties and regulation of PAI-1, and then speculate about its potential role in vascular disease, fibrosis, obesity and the metabolic syndrome, and cancer.
尽管纤溶酶原激活物抑制剂1(PAI-1)是纤维蛋白溶解系统的主要调节因子之一,但它对细胞黏附、脱离和迁移也有显著影响。PAI-1与其他丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制剂家族)也有所不同,它是血浆中的一种微量蛋白,在体内半衰期短,其合成受到高度调节,并且它以高亲和力和特异性与黏附糖蛋白玻连蛋白(VN)结合。PAI-1这些独特多样的特性可能解释了文献中许多将PAI-1基因表达异常与多种病理状况相关联的观察结果。在这篇综述中,我们讨论了PAI-1的发现、起源、特性和调节,然后推测了它在血管疾病、纤维化、肥胖和代谢综合征以及癌症中的潜在作用。